FATE logo

Fate Therapeutics (FATE)

Profile

Full Name

Fate Therapeutics, Inc.

Ticker Symbol

FATE

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

October 1, 2013

Indexes

Not included

Website

http://www.fatetherapeutics.com

Employees

181

Key Details

Price

$1.02(+10.78%)

Market cap

$116.80M(Small cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$13.63M(-78.55% YoY)

Annual EPS

-$1.64(0.00% YoY)

PE ratio

-

Next earnings date

May 9, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$1.02
FATE price is $1.02

30-Day Relative Volume

1.19
FATE 30-day relative volume is 1.19

Price Performance

Price Today change

+10.78%
FATE price is up +10.78% today

Price YTD change

-38.23%
FATE price is down -38.23% since January 1st

Price 1-year change

-81.93%
FATE price is down -81.93% year-on-year

Price 3-year change

-97.3%
FATE price is down -97.3% over the past 3 years

Price Range

Price All-time high

$121.16
FATE price is currently -99.16% below its historical high of $121.16

Price 3-year low

$0.66
FATE price is currently +54.42% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$116.80M
FATE market capitalization is $116.80 million

Market cap 3-year change

-96.8%
FATE market capitalization is down -96.8% over the past 3 years

Market cap All-time high

$10.90B
FATE market capitalization is currently -98.93% below its historical high of $10.90 billion

Market cap sector rank

50.58%
FATE market capitalization is higher than 50.58% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+0.69%
FATE shares outstanding is up +0.69% year-on-year

Shares Outstanding 3-Year Change

+18.65%
FATE shares outstanding is up +18.65% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

1.01
FATE beta is 1.01

200-day SMA

$2.50
FATE price is currently -59.15% below its 200-day simple moving average

50-day SMA

$1.07
FATE price is currently -4.64% below its 50-day simple moving average

RSI

48.67
FATE 14-day relative strength index is 48.67

Volume

1.19
FATE 30-day relative volume is 1.19

ATR

$0.14
FATE average true range is $0.14

10-day Historical Volatility

168.67%
FATE 10-day historical volatility is 168.67%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$13.63M
FATE annual revenue is $13.63 million

Revenue Analysts estimate

$4.59M
FATE annual revenue is currently +196.91% higher than the consensus analysts' forecast

Revenue 1-year change

-78.55%
FATE annual revenue is down -78.55% year-on-year

Revenue Sector rank

31.47%
FATE annual revenue is higher than 31.47% of companies in Healthcare sector

EPS

EPS

-$1.64
FATE annual earnings per share is -$1.64

EPS Analysts estimate

-$1.46
FATE annual earnings per share is currently +12.48% higher than the consensus analysts' forecast

EPS 1-year change

0%
FATE {parameterFullLabel} has remained unchanged year-on-year

EPS Sector rank

42.85%
FATE annual earnings per share is higher than 42.85% of companies in Healthcare sector

Profit

Gross profit

-
FATE annual gross profit value is unknown

Gross margin

-
FATE annual gross profit margin value is unknown

Operating profit

-$195.54M
FATE annual operating income is -$195.54 million

Operating margin

-1434.52%
FATE annual operating profit margin is -1434.52%

Net income

-$186.26M
FATE annual net profit is -$186.26 million

Net margin

-1366.46%
FATE annual net profit margin is -1366.46%

Expenses

Total expenses

$209.17M
FATE annual total expenses is $209.17 million

Operating expenses

$209.17M
FATE annual total operating expenses is $209.17 million

Cost of goods sold

-
FATE annual cost of goods sold value is unknown

Selling, general & administrative expenses

$74.17M
FATE annual SGA is $74.17 million

Depreciation and amortization

$18.96M
FATE annual depreciation & amortization is $18.96 million

Interest expense

-
FATE annual interest expense value is unknown

Income tax

-
FATE annual income tax value is unknown

EBIT & EBITDA

EBIT

-$195.54M
FATE annual earnings before interest & taxes is -$195.54 million

EBITDA

-$176.58M
FATE annual EBITDA is -$176.58 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$440.69M
FATE annual total assets is $440.69 million

Non current assets

$148.78M
FATE annual long term assets is $148.78 million

Current assets

$291.91M
FATE annual total current assets is $291.91 million

Cash and cash equivalents

$36.06M
FATE annual cash & cash equivalents is $36.06 million

Accounts receivable

$3.54M
FATE annual accounts receivable is $3.54 million

Inventory

-
FATE annual inventory value is unknown

Liabilities

Total liabilities

$121.97M
FATE annual total liabilities is $121.97 million

Long term liabilities

$83.45M
FATE annual total long term liabilities is $83.45 million

Current liabilities

$38.52M
FATE annual total current liabilities is $38.52 million

Accounts payable

$9.37M
FATE annual accounts payable is $9.37 million

Debt

Total debt

$85.27M
FATE annual total debt is $85.27 million

Total debt 1-year change

-17.65%
FATE annual total debt is down -17.65% year-on-year

Long term debt

$77.85M
FATE annual long term debt is $77.85 million

Short term debt

$7.42M
FATE annual short term debt is $7.42 million

Equity & Capital

Shareholders equity

$318.73M
FATE annual stockholders equity is $318.73 million

Book value

$318.72M
FATE annual book value is $318.72 million

Retained earnings

-$1.40B
FATE annual retained earnings is -$1.40 billion

Working capital

$253.39M
FATE annual working capital is $253.39 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$122.87M
FATE annual cash flow from operations is -$122.87 million

Cash from operations 1-year change

+7.1%
FATE annual cash flow from operations is up +7.1% year-on-year

Cash from investing

$12.22M
FATE annual cash flow from investing activities is $12.22 million

Cash from investing 1-year change

-89.16%
FATE annual cash flow from investing activities is down -89.16% year-on-year

Cash from financing

$99.89M
FATE annual cash flow from financing activities is $99.89 million

Cash from financing 1-year change

+117420%
FATE annual cash flow from financing activities is up +117420% year-on-year

CAPEX

CAPEX

$730.00K
FATE annual capital expenditures is $730.00 thousand

CAPEX 1-year change

-88.14%
FATE annual capital expenditures is down -88.14% year-on-year

Free Cash Flow

Free cash flow

-$123.60M
FATE annual free cash flow is -$123.60 million

Free cash flow 1-year change

+10.7%
FATE annual free cash flow is up +10.7% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

-
FATE annual gross profit margin value is unknown

Operating margin

-1434.52%
FATE annual operating profit margin is -1434.52%

Net margin

-1366.46%
FATE annual net profit margin is -1366.46%

ROA & ROE

ROA

-39.34%
FATE annual return on assets is -39.34%

ROE

-54.21%
FATE annual return on equity is -54.21%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
FATE price to earnings ratio value is unknown

PE ratio Sector rank

-
FATE price to earnings ratio is unknown

PB Ratio

PB ratio

0.37
FATE price to book ratio is 0.37

PB ratio Sector rank

25.43%
FATE price to book ratio is higher than 25.43% of companies in Healthcare sector

PS Ratio

PS ratio

8.57
FATE price to sales ratio is 8.57

PS ratio Sector rank

76.41%
FATE price to sales ratio is higher than 76.41% of companies in Healthcare sector

Enterprise value

Enterprise value

$166.01M
FATE enterprise value is $166.01 million

Enterprise value Sector rank

55.87%
FATE enterprise value is higher than 55.87% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-0.94
FATE EV/EBITDA is -0.94

EV/EBITDA Sector rank

44.09%
FATE EV/EBITDA is higher than 44.09% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

7.58
FATE annual current ratio is 7.58

Quick ratio

-
FATE annual quick ratio value is unknown

Leverage

Debt to equity

0.00
FATE annual debt to equity ratio is 0.00

Interest coverage ratio

-
FATE annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

-
FATE piotroski f-score value is unknown

Altman Z-Score

-4.61
FATE altman z-score is -4.61

Analyst ratings

Recent major analysts updates

Mar 6, 25 Wells Fargo
Equal-Weight
Mar 6, 25 Wedbush
Neutral
Mar 6, 25 Stifel
Hold
Mar 6, 25 Needham
Hold
Nov 19, 24 Needham
Hold
Nov 13, 24 Needham
Hold
Aug 22, 24 HC Wainwright & Co.
Neutral
Aug 14, 24 Needham
Hold
Jun 17, 24 Piper Sandler
Overweight
May 16, 24 HC Wainwright & Co.
Neutral

Institutional Ownership

Similar stocks

IRWD logo
Ironwood Pharmaceuticals (IRWD)
ENTA logo
Enanta Pharmaceuticals (ENTA)
INFU logo
InfuSystem Holdings (INFU)
AIRS logo
AirSculpt Technologies (AIRS)
TNXP logo
Tonix Pharmaceuticals Holding (TNXP)
OBIO logo
Orchestra BioMed Holdings (OBIO)
SLS logo
SELLAS Life Sciences (SLS)
Contineum Therapeutics Class A (CTNM)
LUCD logo
Lucid Diagnostics (LUCD)
  • What is the ticker symbol for Fate Therapeutics?
  • Does Fate Therapeutics pay dividends?
  • What sector is Fate Therapeutics in?
  • What industry is Fate Therapeutics in?
  • What country is Fate Therapeutics based in?
  • When did Fate Therapeutics go public?
  • Is Fate Therapeutics in the S&P 500?
  • Is Fate Therapeutics in the NASDAQ 100?
  • Is Fate Therapeutics in the Dow Jones?
  • When was Fate Therapeutics's last earnings report?
  • When does Fate Therapeutics report earnings?
  • Should I buy Fate Therapeutics stock now?

What is the ticker symbol for Fate Therapeutics?

The ticker symbol for Fate Therapeutics is NASDAQ:FATE

Does Fate Therapeutics pay dividends?

No, Fate Therapeutics does not pay dividends

What sector is Fate Therapeutics in?

Fate Therapeutics is in the Healthcare sector

What industry is Fate Therapeutics in?

Fate Therapeutics is in the Biotechnology industry

What country is Fate Therapeutics based in?

Fate Therapeutics is headquartered in United States

When did Fate Therapeutics go public?

Fate Therapeutics's initial public offering (IPO) was on October 1, 2013

Is Fate Therapeutics in the S&P 500?

No, Fate Therapeutics is not included in the S&P 500 index

Is Fate Therapeutics in the NASDAQ 100?

No, Fate Therapeutics is not included in the NASDAQ 100 index

Is Fate Therapeutics in the Dow Jones?

No, Fate Therapeutics is not included in the Dow Jones index

When was Fate Therapeutics's last earnings report?

Fate Therapeutics's most recent earnings report was on Mar 5, 2025

When does Fate Therapeutics report earnings?

The next expected earnings date for Fate Therapeutics is May 9, 2025

Should I buy Fate Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page